vs

Side-by-side financial comparison of Crane NXT, Co. (CXT) and Sotera Health Co (SHC). Click either name above to swap in a different company.

Crane NXT, Co. is the larger business by last-quarter revenue ($476.9M vs $303.4M, roughly 1.6× Sotera Health Co). Sotera Health Co runs the higher net margin — 11.5% vs 10.0%, a 1.5% gap on every dollar of revenue. On growth, Crane NXT, Co. posted the faster year-over-year revenue change (19.5% vs 4.6%). Over the past eight quarters, Crane NXT, Co.'s revenue compounded faster (23.3% CAGR vs 10.6%).

Crane Co. is an American industrial products company based in Stamford, Connecticut. Founded by Richard Teller Crane in 1855, it became one of the leading manufacturers of bathroom fixtures in the United States, until 1990, when that division was sold off. In 1960 it began the process of becoming a holding company with a diverse portfolio. Its business segments are Aerospace & Electronics, Engineered Materials, Fluid Handling, and Controls. Industries served by these segments include chemical...

Sotera Health Co is a global provider of end-to-end medical safety solutions. It offers sterilization services, analytical laboratory testing, and regulatory advisory support for medical device manufacturers, pharmaceutical firms, and food and consumer product companies, helping clients meet industry standards and ensure product safety for end users worldwide.

CXT vs SHC — Head-to-Head

Bigger by revenue
CXT
CXT
1.6× larger
CXT
$476.9M
$303.4M
SHC
Growing faster (revenue YoY)
CXT
CXT
+14.9% gap
CXT
19.5%
4.6%
SHC
Higher net margin
SHC
SHC
1.5% more per $
SHC
11.5%
10.0%
CXT
Faster 2-yr revenue CAGR
CXT
CXT
Annualised
CXT
23.3%
10.6%
SHC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CXT
CXT
SHC
SHC
Revenue
$476.9M
$303.4M
Net Profit
$47.5M
$34.8M
Gross Margin
42.4%
54.7%
Operating Margin
16.7%
23.2%
Net Margin
10.0%
11.5%
Revenue YoY
19.5%
4.6%
Net Profit YoY
182.8%
EPS (diluted)
$0.82
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CXT
CXT
SHC
SHC
Q4 25
$476.9M
$303.4M
Q3 25
$445.1M
$311.3M
Q2 25
$404.4M
$294.3M
Q1 25
$330.3M
$254.5M
Q4 24
$399.1M
$290.2M
Q3 24
$403.5M
$285.5M
Q2 24
$370.6M
$276.6M
Q1 24
$313.6M
$248.2M
Net Profit
CXT
CXT
SHC
SHC
Q4 25
$47.5M
$34.8M
Q3 25
$50.5M
$48.4M
Q2 25
$24.9M
$8.0M
Q1 25
$21.7M
$-13.3M
Q4 24
$12.3M
Q3 24
$47.1M
$17.0M
Q2 24
$41.6M
$8.8M
Q1 24
$37.8M
$6.3M
Gross Margin
CXT
CXT
SHC
SHC
Q4 25
42.4%
54.7%
Q3 25
43.3%
57.0%
Q2 25
41.7%
56.6%
Q1 25
42.4%
53.2%
Q4 24
45.2%
56.6%
Q3 24
42.5%
55.4%
Q2 24
43.4%
55.2%
Q1 24
48.6%
51.2%
Operating Margin
CXT
CXT
SHC
SHC
Q4 25
16.7%
23.2%
Q3 25
18.4%
23.4%
Q2 25
11.8%
6.4%
Q1 25
11.3%
-5.8%
Q4 24
17.7%
30.0%
Q3 24
18.6%
28.2%
Q2 24
18.2%
27.8%
Q1 24
17.7%
21.4%
Net Margin
CXT
CXT
SHC
SHC
Q4 25
10.0%
11.5%
Q3 25
11.3%
15.5%
Q2 25
6.2%
2.7%
Q1 25
6.6%
-5.2%
Q4 24
4.2%
Q3 24
11.7%
6.0%
Q2 24
11.2%
3.2%
Q1 24
12.1%
2.5%
EPS (diluted)
CXT
CXT
SHC
SHC
Q4 25
$0.82
$0.12
Q3 25
$0.87
$0.17
Q2 25
$0.43
$0.03
Q1 25
$0.38
$-0.05
Q4 24
$1.00
$0.05
Q3 24
$0.81
$0.06
Q2 24
$0.72
$0.03
Q1 24
$0.66
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CXT
CXT
SHC
SHC
Cash + ST InvestmentsLiquidity on hand
$233.8M
$344.6M
Total DebtLower is stronger
$1.0B
$2.1B
Stockholders' EquityBook value
$1.3B
$606.0M
Total Assets
$3.1B
$3.3B
Debt / EquityLower = less leverage
0.80×
3.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CXT
CXT
SHC
SHC
Q4 25
$233.8M
$344.6M
Q3 25
$182.4M
$299.2M
Q2 25
$152.5M
$332.4M
Q1 25
$173.8M
$304.4M
Q4 24
$165.8M
$277.2M
Q3 24
$165.1M
$306.7M
Q2 24
$175.5M
$246.1M
Q1 24
$220.6M
$261.1M
Total Debt
CXT
CXT
SHC
SHC
Q4 25
$1.0B
$2.1B
Q3 25
$834.3M
$2.1B
Q2 25
$861.8M
$2.2B
Q1 25
$541.1M
$2.2B
Q4 24
$540.6M
$2.2B
Q3 24
$638.2M
$2.2B
Q2 24
$638.9M
$2.2B
Q1 24
$639.6M
$2.2B
Stockholders' Equity
CXT
CXT
SHC
SHC
Q4 25
$1.3B
$606.0M
Q3 25
$1.2B
$550.5M
Q2 25
$1.2B
$511.3M
Q1 25
$1.1B
$414.1M
Q4 24
$1.1B
$404.9M
Q3 24
$1.1B
$470.2M
Q2 24
$989.8M
$422.8M
Q1 24
$964.1M
$429.4M
Total Assets
CXT
CXT
SHC
SHC
Q4 25
$3.1B
$3.3B
Q3 25
$2.9B
$3.2B
Q2 25
$2.9B
$3.2B
Q1 25
$2.4B
$3.1B
Q4 24
$2.4B
$3.1B
Q3 24
$2.4B
$3.1B
Q2 24
$2.4B
$3.1B
Q1 24
$2.1B
$3.1B
Debt / Equity
CXT
CXT
SHC
SHC
Q4 25
0.80×
3.53×
Q3 25
0.69×
3.89×
Q2 25
0.73×
4.34×
Q1 25
0.49×
5.36×
Q4 24
0.51×
5.49×
Q3 24
0.60×
4.73×
Q2 24
0.65×
5.26×
Q1 24
0.66×
5.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CXT
CXT
SHC
SHC
Operating Cash FlowLast quarter
$105.8M
$103.1M
Free Cash FlowOCF − Capex
$52.4M
FCF MarginFCF / Revenue
17.3%
Capex IntensityCapex / Revenue
16.7%
Cash ConversionOCF / Net Profit
2.23×
2.96×
TTM Free Cash FlowTrailing 4 quarters
$149.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CXT
CXT
SHC
SHC
Q4 25
$105.8M
$103.1M
Q3 25
$92.0M
$71.2M
Q2 25
$62.8M
$57.4M
Q1 25
$-19.1M
$55.5M
Q4 24
$81.1M
$55.7M
Q3 24
$66.7M
$97.5M
Q2 24
$56.8M
$61.3M
Q1 24
$9.5M
$9.7M
Free Cash Flow
CXT
CXT
SHC
SHC
Q4 25
$52.4M
Q3 25
$78.7M
$35.0M
Q2 25
$55.8M
$26.2M
Q1 25
$-32.2M
$35.6M
Q4 24
$-10.2M
Q3 24
$53.5M
$61.1M
Q2 24
$47.9M
$19.4M
Q1 24
$-3.0M
$-25.2M
FCF Margin
CXT
CXT
SHC
SHC
Q4 25
17.3%
Q3 25
17.7%
11.2%
Q2 25
13.8%
8.9%
Q1 25
-9.7%
14.0%
Q4 24
-3.5%
Q3 24
13.3%
21.4%
Q2 24
12.9%
7.0%
Q1 24
-1.0%
-10.2%
Capex Intensity
CXT
CXT
SHC
SHC
Q4 25
16.7%
Q3 25
3.0%
11.6%
Q2 25
1.7%
10.6%
Q1 25
4.0%
7.8%
Q4 24
22.7%
Q3 24
3.3%
12.7%
Q2 24
2.4%
15.2%
Q1 24
4.0%
14.1%
Cash Conversion
CXT
CXT
SHC
SHC
Q4 25
2.23×
2.96×
Q3 25
1.82×
1.47×
Q2 25
2.52×
7.21×
Q1 25
-0.88×
Q4 24
4.52×
Q3 24
1.42×
5.73×
Q2 24
1.37×
7.00×
Q1 24
0.25×
1.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CXT
CXT

Other$260.9M55%
Products$181.1M38%
Services$34.9M7%

SHC
SHC

Transferred At Point In Time$198.4M65%
Nelson Labs$55.2M18%
Nordion$49.8M16%

Related Comparisons